Pfizer moves to cap retiree health benefits

In further evidence of out-of-control healthcare costs, Pfizer is joining the U.S. companies capping retiree health benefits, with the size of retiree medical subsidies determined by years of service. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.